# US 12,006,311 B2 · Compounds for use in preventing or treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,311 B2
- Document ID: US12006311B2
- Status: Granted
- Kind: B2
- Application number: 17/256,837
- Filed: 2019-07-01
- Published: 2021-07-29
- Granted: 2024-06-11
- Earliest claimed: 2018-06-29
- Assignees: Fundació Hospital Universitari Vall D'Hebroninstitut De Recerca; Institut Univ. De CièNcia I Tecnologia, S. A.
- Applicants: Fundació Hospital Universitari Vall D'Hebron—Institut De Recerca; Institut Univ. De CièNcia I Tecnologia, S. A.
- Inventors: Josep Roma Castanyer; Marta Pascual Gilabert; José Sánchez De Toledo Codina; Soledad Gallego Melcón; Patricia Zarzosa Martínez; Javier Alonso Fernández; Sergio Pérez Ozcáriz; Cristina López Gómez; Josep Castells Boliart
- Web page: https://patentgrep.com/patent/US12006311B2

## CPC

- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- C07D 409/14: containing three or more hetero rings
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of formula (I) for use in preventing and/or treating cancer.

## Claims

### Claim 1

A compound selected from the group consisting of:
4,5-Dichloro-N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)thiophene-2-sulfonamide;
N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-3,5-dimethylisoxazole-4-sulfonamide;
N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)benzo[d][1,3] dioxole-5-sulfonamide;
N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-5-(pyridin-2-yl)thiophene-2-sulfonamide;
N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)benzofuran-2-sulfonamide;
4,5-Dichloro-N-(cyanomethyl)-N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)thiophene-2-sulfonamide;
Ethyl N-(benzo[d][1,3]dioxol-5-ylsulfonyl)-N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)glycinate;
N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-N-(2-morpholino-2-oxoethyl)benzo[d][1,3]dioxole-5-sulfonamide;
2-((4,5-dichloro-N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)thiophene)-2-sulfonamido)acetamide; and
Ethyl N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-N-((5-(pyridin-2-yl)thiophen-2-yl)sulfonyl)glycinate;
or a salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, which is N-(1-(3-fluoro-2′-methoxy-[1,1′-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-5-(pyridin-2-yl)thiophene-2-sulfonamide.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein the compound inhibits cell proliferation of a cancer cell, wherein the cancer is lung cancer, prostate cancer, colorectal cancer, breast cancer, cervical cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, or osteosarcoma.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein the compound inhibits cell proliferation of a cancer cell, wherein the cancer is epitheloid cervix carcinoma, basal cell carcinoma, melanoma, ovarian cancer, cervical cancer, pancreatic cancer, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, medulloblastoma, glioblastoma, astrocytoma, neuroblastoma, prostate cancer, lung cancer or breast cancer.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein the compound inhibits cell proliferation of a cancer cell, wherein the cancer is rhabdomyosarcoma, neuroblastoma, glioblastoma, Ewing's sarcoma, prostate cancer, epitheloid cervix carcinoma, lung cancer or breast cancer.

### Claim 6 (depends on 1)

A combination comprising a compound according to claim 1 and compound selected from the group consisting of a chemotherapeutic agent; an antimetabolite; a spindle poison plant alkaloid; a cytotoxic/antitumour antibiotic; a topoisomerase inhibitor; an antibody; a photosensitizer; a kinase inhibitor; a pathway-specific inhibitor; an anti-hormonal agent; an aromatase inhibitor; an anti-androgen; a ribozyme; a vaccine; an anti-angiogenic agent; and an antiviral agent; or a combination thereof.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the composition is formulated for administration by an oral, rectal, nasal, ocular, topical, vaginal, parenteral, transdermal, intraperitoneal, intrapulmonary or intranasal route.

### Claim 9 (depends on 1)

A method of treating a cancer selected from the group consisting of lung cancer, prostate cancer, colorectal cancer, breast cancer, cervical cancer, glioblastoma, neuroblastoma, rhabdomyosarcoma, or osteosarcoma, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

### Claim 10 (depends on 9)

The method of claim 9, further comprising the step of administering a compound selected from the group consisting of a chemotherapeutic agent; an antimetabolite; a spindle poison plant alkaloid; a cytotoxic/antitumour antibiotic; a topoisomerase inhibitor; an antibody; a photosensitizer; a kinase inhibitor; a pathway-specific inhibitor; an anti-hormonal agent; an aromatase inhibitor; an anti-androgen; a ribozyme; a vaccine; an anti-angiogenic agent; and an antiviral agent; or a combination thereof.

### Claim 11 (depends on 9)

The method of claim 9, wherein said compound is included in a pharmaceutical composition.

### Claim 12 (depends on 9)

The method of claim 9, wherein said compound is administered by oral, rectal, nasal, ocular, topical, vaginal, parenteral, transdermal, intraperitoneal, intrapulmonary or intranasal route.

### Claim 13 (depends on 9)

The method of claim 9, wherein said compound is administered in combination with surgical therapy, radiotherapy, immunotherapy, epigenetic therapy or a combination thereof.

### Claim 14 (depends on 1)

A method of treating a cancer selected from the group consisting of epitheloid cervix carcinoma, basal cell carcinoma, melanoma, ovarian cancer, cervical cancer, pancreatic cancer, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, medulloblastoma, glioblastoma, astrocytoma, neuroblastoma, prostate cancer, lung cancer or breast cancer, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

### Claim 15 (depends on 1)

A method of treating a cancer selected from the group consisting of rhabdomyosarcoma, neuroblastoma, glioblastoma, Ewing's sarcoma, prostate cancer, epitheloid cervix carcinoma, lung cancer or breast cancer, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.